Study Title

The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal Cancer (peritoneal Metastasis With/without Other Metastases)

Study Details

Description:

This study aims to investigate the value of 18F-FDG and 68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of advanced colorectal cancer (peritoneal metastasis with/without other metastases)

Sponsor:

Ruijin Hospital

Government Study Link:

NCT06601075 - Click here to see study on

ClinicalTrials.gov

Drug Details

18F-FDG
Isotope(s):
    FLUORINE-18
    Radioisotope: F-18
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 1.8 Hours
    Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
    Energy: Eβ+ 635 keV
    Range: N/A
    Decay Daughters: O18 (Stable)
    Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
  • FLUORINE-18
Target(s):
Ga68-FAPI
Isotope(s):
    GALLIUM-68
    Radioisotope: Ga-68
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 68 minutes
    Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
    Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
    Range: N/A
    Decay Daughters: Zn68 (Stable)
    Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
  • GALLIUM-68
Target(s):
  • FAP

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468